{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:37:08Z","timestamp":1783687028729,"version":"3.55.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.00049","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T10:12:52Z","timestamp":1581070372000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["Mangiferin Ameliorates Hyperuricemic Nephropathy Which Is Associated With Downregulation of AQP2 and Increased Urinary Uric Acid Excretion"],"prefix":"10.3389","volume":"11","author":[{"given":"Xuechen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Carlstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinying","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"key":"B46","doi-asserted-by":"publisher","first-page":"26834","DOI":"10.1074\/jbc.C800156200","article-title":"Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans","volume":"283","author":"Anzai","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3109\/0886022X.2014.882240","article-title":"Circulating purine compounds, uric acid, and xanthine oxidase\/dehydrogenase relationship in essential hypertension and end stage renal disease","volume":"36","author":"Boban","year":"2014","journal-title":"Renal Fail."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/srep39884","article-title":"Soluble Uric Acid Activates the NLRP3 Inflammasome","volume":"7","author":"Braga","year":"2017","journal-title":"Sci. Rep."},{"key":"B39","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/01.mnh.0000444814.49755.90","article-title":"The emerging role of the inflammasome in kidney diseases","volume":"23","author":"Chang","year":"2014","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"B50","doi-asserted-by":"publisher","first-page":"F29","DOI":"10.1152\/ajprenal.2000.278.1.F29","article-title":"Localization and regulation of PKA-phosphorylated AQP2 in response to V(2)-receptor agonist\/antagonist treatment","volume":"278","author":"Christensen","year":"2000","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3109\/13813455.2014.924145","article-title":"Serum uric acid levels and metabolic syndrome","volume":"120","author":"Ciarla","year":"2014","journal-title":"Arch. Physiol. Biochem."},{"key":"B48","first-page":"495","article-title":"Pathogenesis, clinical findings and management of acute and chronic gout","volume":"97","author":"Corrado","year":"2006","journal-title":"Minerva Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00467-018-4005-4","article-title":"Oxidative stress in chronic kidney disease","volume":"34","author":"Daenen","year":"2019","journal-title":"Pediatr. Nephrol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1124\/jpet.109.154179","article-title":"c-Jun NH2-terminal kinase is crucially involved in renal tubulo-interstitial inflammation","volume":"331","author":"de Borst","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1758-5996-4-12","article-title":"High plasma uric acid concentration: causes and consequences","volume":"4","author":"de Oliveira","year":"2012","journal-title":"Diabetol. Metab. Syndr."},{"key":"B51","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/art.1780150403","article-title":"Effect of urine flow rate on uric acid excretion in man","volume":"15","author":"Diamond","year":"1972","journal-title":"Arthritis Rheum."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"New Engl. J. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11926-012-0309-8","article-title":"Genetics of hyperuricemia and gout: implications for the present and future","volume":"15","author":"George","year":"2013","journal-title":"Curr. Rheumatol. Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1081\/DMR-120037569","article-title":"Physiological roles of xanthine oxidoreductase","volume":"36","author":"Harrison","year":"2004","journal-title":"Drug Metab. Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1159\/000369220","article-title":"Mangiferin attenuate sepsis-induced acute kidney injury via antioxidant and anti-inflammatory effects","volume":"40","author":"He","year":"2014","journal-title":"Am. J. Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/01.ASN.0000107560.80107.19","article-title":"Function and localization of urate transporter 1 in mouse kidney","volume":"15","author":"Hosoyamada","year":"2004","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"key":"B34","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1139\/cjpp-2015-0073","article-title":"Mangiferin suppressed advanced glycation end products (AGEs) through NF-kappaB deactivation and displayed anti-inflammatory effects in streptozotocin and high fat diet-diabetic cardiomyopathy rats","volume":"94","author":"Hou","year":"2016","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/ncomms1756","article-title":"Decreased extra-renal urate excretion is a common cause of hyperuricemia","volume":"3","author":"Ichida","year":"2012","journal-title":"Nat. Commun."},{"key":"B32","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.semnephrol.2011.08.011","article-title":"Uric acid as a mediator of diabetic nephropathy","volume":"31","author":"Jalal","year":"2011","journal-title":"Semin. Nephrol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.ajkd.2012.07.021","article-title":"Uric acid as a target of therapy in CKD","volume":"61","author":"Jalal","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1093\/ndt\/gft029","article-title":"Uric acid and chronic kidney disease: which is chasing which","volume":"28","author":"Johnson","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002725","article-title":"No causal effects of serum urate levels on the risk of chronic kidney disease: a Mendelian randomization study","volume":"16","author":"Jordan","year":"2019","journal-title":"PloS Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1097\/01.ASN.0000034910.58454.FD","article-title":"A role for uric acid in the progression of renal disease","volume":"13","author":"Kang","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/hep.20634","article-title":"Mechanisms of benzarone and benzbromarone-induced hepatic toxicity","volume":"41","author":"Kaufmann","year":"2005","journal-title":"Hepatology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1093\/ndt\/gfn729","article-title":"Protein kinase C-beta inhibition attenuates the progression of nephropathy in non-diabetic kidney disease","volume":"24","author":"Kelly","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"B17","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","article-title":"A benefit-risk assessment of benzbromarone in the treatment of gout Was its withdrawal market In best interest patients?","volume":"31","author":"Lee","year":"2008","journal-title":"Drug Saf."},{"key":"B33","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/ptr.3045","article-title":"Mangiferin prevents diabetic nephropathy progression in streptozotocin-induced diabetic rats","volume":"24","author":"Li","year":"2010","journal-title":"Phytother. Res."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/srep03755","article-title":"ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload","volume":"4","author":"Matsuo","year":"2014","journal-title":"Sci. Rep."},{"key":"B52","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1042\/cs0510033","article-title":"Effect of vasopressin on uric acid excretion: evidence for distal nephron reabsorption of urate in man","volume":"51","author":"Meisel","year":"1976","journal-title":"Clin. Sci. Mol. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/jps.2600650615","article-title":"Urinary excretion of probenecid and its metabolites in humans as a function of dose","volume":"65","author":"Melethil","year":"1976","journal-title":"J. Pharm. Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"40305","DOI":"10.18632\/oncotarget.16928","article-title":"Baicalein decreases uric acid and prevents hyperuricemic nephropathy in mice","volume":"8","author":"Meng","year":"2017","journal-title":"Oncotarget"},{"key":"B47","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s13075-016-1107-x","article-title":"Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney","volume":"18","author":"Miner","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0300-483X(02)00069-0","article-title":"Mangiferin protects the streptozotocin-induced oxidative damage to cardiac and renal tissues in rats","volume":"176","author":"Muruganandan","year":"2002","journal-title":"Toxicology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1080\/15257770.2016.1163379","article-title":"Uric acid metabolism of kidney and intestine in a rat model of chronic kidney disease","volume":"35","author":"Nagura","year":"2016","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"B13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1152\/physrev.00025.2013","article-title":"The organic anion transporter (OAT) family: a systems biology perspective","volume":"95","author":"Nigam","year":"2015","journal-title":"Physiol. Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.3109\/13880209.2012.663763","article-title":"Reducing effect of mangiferin on serum uric acid levels in mice","volume":"50","author":"Niu","year":"2012","journal-title":"Pharm. Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.3109\/13880209.2015.1120322","article-title":"Hypouricaemic action of mangiferin results from metabolite norathyriol via inhibiting xanthine oxidase activity","volume":"54","author":"Niu","year":"2016","journal-title":"Pharm. Biol."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075527","article-title":"Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK","volume":"8","author":"Nomura","year":"2013","journal-title":"PloS One"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107220","article-title":"Mangiferin attenuates diabetic nephropathy by inhibiting oxidative stress mediated signaling cascade, TNFalpha related and mitochondrial dependent apoptotic pathways in streptozotocin-induced diabetic rats","volume":"9","author":"Pal","year":"2014","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13543776.2016.1213243","article-title":"Urate transporter URAT1 inhibitors: a patent review (2012\u20132015)","volume":"26","author":"Pan","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"B1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","article-title":"Gout","volume":"375","author":"Richette","year":"2010","journal-title":"Lancet"},{"key":"B42","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1523-1755.2005.00074.x","article-title":"Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats","volume":"67","author":"Sanchez-Lozada","year":"2005","journal-title":"Kidney Int."},{"key":"B43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000127837","article-title":"Effect of febuxostat on the progression of renal disease in 5\/6 nephrectomy rats with and without hyperuricemia","volume":"108","author":"Sanchez-Lozada","year":"2008","journal-title":"Nephron Physiol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/ndt\/gfm783","article-title":"Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia","volume":"23","author":"Sanchez-Lozada","year":"2008","journal-title":"Nephrol. Dial. Transplant."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1159\/000345509","article-title":"Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations","volume":"121","author":"Sanchez-Lozada","year":"2012","journal-title":"Nephron. Exp. Nephrol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/14728214.2018.1527899","article-title":"Expert opinion on emerging urate-lowering therapies","volume":"23","author":"Stamp","year":"2018","journal-title":"Expert Opin. Emerg Drugs"},{"key":"B15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5599\/admet.5.2.387","article-title":"Uric acid transporter inhibitors for gout","volume":"5","author":"Tan","year":"2017","journal-title":"ADMET DMPK"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/srep34995","article-title":"Mechanism of high affinity inhibition of the human urate transporter URAT1","volume":"6","author":"Tan","year":"2016","journal-title":"Sci. Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1517\/13543776.2013.836182","article-title":"Therapeutic and cosmetic applications of mangiferin: a patent review","volume":"23","author":"Telang","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"B38","doi-asserted-by":"publisher","first-page":"F373","DOI":"10.1152\/ajprenal.00208.2016","article-title":"ASK1: a new therapeutic target for kidney disease","volume":"311","author":"Tesch","year":"2016","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1111\/j.1523-1755.2004.00798.x","article-title":"High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy","volume":"66","author":"Toyoda","year":"2004","journal-title":"Kidney Int."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.2337\/diacare.28.11.2686","article-title":"The effect of ruboxistaurin on nephropathy in type 2 diabetes","volume":"28","author":"Tuttle","year":"2005","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/ng.106","article-title":"SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout","volume":"40","author":"Vitart","year":"2008","journal-title":"Nat. Genet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.biopha.2017.10.022","article-title":"Mangiferin ameliorates fatty liver via modulation of autophagy and inflammation in high-fat-diet induced mice","volume":"96","author":"Wang","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"B45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/RHU.0b013e318204aab4","article-title":"Renal function in gout long-term treatment effects of febuxostat","volume":"17","author":"Whelton","year":"2011","journal-title":"J. Clin. Rheumatol."},{"key":"B59","article-title":"New mouse model of gout risk variant, ABCG2 Q141K, reveals unexpectedly severe molecular and functional defect in ABCG2 mediated intestinal uric acid secretion [abstract]","volume":"69","author":"Woodward","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"10338","DOI":"10.1073\/pnas.0901249106","article-title":"Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout","volume":"106","author":"Woodward","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B56","doi-asserted-by":"publisher","first-page":"F485","DOI":"10.1152\/ajprenal.00242.2015","article-title":"ABCG2: the molecular mechanisms of urate secretion and gout","volume":"309","author":"Woodward","year":"2015","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1248\/bpb.b15-00402","article-title":"Mangiferin Inhibits Renal Urate Reabsorption by Modulating Urate Transporters in Experimental Hyperuricemia","volume":"38","author":"Yang","year":"2015","journal-title":"Biol. Pharm. Bull."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00049\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T10:12:55Z","timestamp":1581070375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00049\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":59,"alternative-id":["10.3389\/fphar.2020.00049"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.00049","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,7]]},"article-number":"49"}}